Table 1.

Cost and utility model inputs.

Input	Value	Source
Costs (per treatment cycle, $ USD)
PDL-1/MMRtesting (once)	456	(24)
Carboplatin/Paclitaxel	1123	(22,24,25)
Pembrolizumab/Lenvatinib	19,986	(22,24,25)
Palliative Care	32,968	(18)
Adverse Event: Hypertension, Grade 3 or 4	8402	(27,28)
Adverse Event: Myelosuppression, Grade 3 or 4	3572	(22)
Health Utility Values
Metastatic Endometrial Cancer	0.63	(31)
Progression	0.36	(30)
Respond	0.71	(30)
Disutility for Grade 3 or 4 Hypertensive event	−0.01	(26,32)
Disutility for Grade 3 or 4 Myelosuppression	−0.10	(30)
Disutility for transition to palliative care	−0.60	(31)